There are significant differences between men and women in the efficacy and tolerability of
antipsychotic drugs. Here, we provide a comprehensive overview of what is currently known …

Metabolic syndrome (MetS), a constellation of central obesity, hypertension, dyslipidaemia
and glucose intolerance, is highly prevalent in individuals with schizophrenia and conveys …

A meta‐analysis was conducted to explore the risk for cardio‐metabolic abnormalities in
drug naïve, first‐episode and multi‐episode patients with schizophrenia and age‐and …

Metabolic syndrome (MetS) is a cluster of factors that increases the risk of cardiovascular
disease (CVD), one of the leading causes of mortality in patients with schizophrenia …

Metabolic syndrome (MetS) has been recognized as a risk factor for cardiovascular
morbidity and mortality in general population and in patients with severe mental illnesses …

Background Patients with schizophrenia have significantly shorter life expectancy than the
general population, and a problem they commonly face is an unhealthy lifestyle, which can …

AIMS: In an Asian population, the criteria for metabolic syndrome (MetS) are different from
those for Western populations. The aim of this study was to assess the MetS prevalence …

Aim: The aim of this study was to design and examine a program called the 'pedometer
walking plus motivational interviewing (PWMI) program'in schizophrenic patients who are …

To review the data with respect to prevalence of metabolic syndrome (MetS) and its
correlates in schizophrenia. For this review, electronic search engines PUBMED …

Patients with schizophrenia could have a higher risk of mortality. We compared the risk of
mortality and the years of potential life lost (YPLL) associated with various causes of death …